Mismatch Repair Deficiency Predicts Response to HER2 Blockade in HER2-Negative Breast Cancer

The authors suggested MutL loss as a predictive marker of sensitivity to combinatorial treatment with endocrine intervention and HER inhibitors in endocrine treatment-resistant ER+/HER2− breast cancer patients.